Table 2. Recipient characteristics.
| GRWR ≤ 0.8% | GRWR > 0.8% | p-value | |
|---|---|---|---|
| Recipients, n | 56 | 239 | – |
| Sex (%) | |||
| Male | 55 (98.21) | 216 (90.38) | 0.058 |
| Female | 1 (1.79) | 23 (9.62) | |
| Age, years, median (interquartile range) | 47.35 (42.70, 52.55) | 48.60 (43.00, 54.40) | 0.714 |
| Body weight, kg, median (interquartile range) | 76.00 (68.50, 82.00) | 67.00 (60.00, 73.50) | <0.001 |
| GW, g, median (interquartile range) | 555.00 (500.00, 607.50) | 680.00 (615.00, 743.00) | <0.001 |
| GRWR median (interquartile range) | 0.74 (0.69, 0.77) | 1.01 (0.90, 1.28) | <0.001 |
| Pre-transplant degradation, n (%) | |||
| Hepatectomy | 1 (1.59) | 9 (3.05) | 0.931 |
| Systemic chemotherapy | 0 (0) | 3 (1.02) | |
| radiofrequency ablation (RFA) | 2 (3.17) | 14 (4.75) | |
| Transcatheter arterial chemoembolization (TACE) | 0 (0) | 64 (22.18) | |
| Percutaneous ethanol injection | 11 (19.64) | 1 (0.42) | |
| Combined treatment | 2 (3.57) | 17 (6.28) | |
| None | 40 (71.43) | 187 (61.51) | |
| Pre-transplant vascular invasion, n (%) | 44 (48.57) | 184 (76.99) | 0.861 |
| History of hepatic encephalopathy | 2 (3.57) | 14 (5.86) | 0.745 |
| History of SBP | 0 (0) | 3 (1.26) | 1.000 |
| AFP level1, ng/mL, median (interquartile range) | 231.60 (9.70, 1210.00) | 107.75 (9.20, 1000.00) | 0.156 |
| Preoperative creatinine2, μmol/L, median (interquartile range) | 65.10 (57.70, 75.60) | 67.00 (58.10, 75.00) | 0.472 |
| Operation duration3, hours, median (interquartile range) | 10.80 (9.50, 12.85) | 10.30 (8.00, 12.50) | 0.489 |
| Blood loss4, mL, median (interquartile range) | 1800.00 (1000.00, 3000.00) | 2000.00 (1000.00, 3000.00) | 0.769 |
| Cold ischemia time5, hours, median (interquartile range) | 0.91 (0.33, 2.50) | 1.48 (0.90, 2.13) | 0.070 |
| Warm ischemia time6, hours, median (interquartile range) | 0.00 (0.00, 0.50) | 0.00 (0.00, 1.00) | 0.017 |
| ICU stay after transplantation7, hours, median (interquartile range) | 144.00 (82.00, 230.00) | 125.00 (72.00, 192.00) | 0.088 |
| Hospital stay after transplantation8, days, median (interquartile range) | 35.00 (28.00, 59.00) | 36.00 (27.00, 51.00) | 0.545 |
| Length of follow-up, months, median (interquartile range) | 11.06 (1.99, 20.59) | 23.78 (8.58, 34.80) | <0.001 |
| Tumor nodules9, n, median (interquartile range) | 1.00 (1.00, 2.50) | 1.00 (1.00, 3.00) | 0.257 |
| Largest tumor diameter10, cm, | |||
| median (interquartile range) | 4.00 (2.60, 5.00) | 3.50 (2.40, 5.50) | 0.701 |
| Sum of tumor diameters11, cm, median (interquartile range) | 5.00 (2.50, 7.50) | 4.10 (2.50, 7.00) | 0.580 |
| Hangzhou criteria12 | |||
| In | 17 (50.00) | 134 (65.69) | 0.086 |
| Out | 17 (50.00) | 70 (34.41) | |
1Ten cases with missing AFP data were excluded.
2Two cases with missing creatinine data were excluded.
3Five cases with missing or abnormal operation time data were excluded.
4Ninety-three cases with missing or abnormal blood loss data were excluded.
5Thirty-seven cases with missing or abnormal cold ischemia time data were excluded.
6Fifty-nine cases with missing or abnormal warm ischemia time data were excluded.
7Five cases with missing, logical paradoxes or abnormal ICU time data were excluded.
8Fifteen cases with missing, logical paradoxes or abnormal hospital time data were excluded.
9Sixty-nine cases with missing nodule or abnormal nodule data were excluded.
10Fifty-two cases with missing size or abnormal size data were excluded.
11Eighty-nine cases with missing sum of tumor diameter or abnormal sum of diameter data were excluded.
12Fifty-seven cases with abnormal tumor feature data were not included in Hangzhou criteria evaluation.